We are live on
!
Find out more
Qube Research & Technologies (QRT) Portfolio holdings
AUM
$89.9B
1-Year Est. Return
20.22%
This Fund
S&P 500
This Quarter
Est. Return
+6.68%
1 Year Est. Return
+20.22%
3 Year Est. Return
+42.42%
5 Year Est. Return
+23.97%
10 Year Est. Return
–
AUM
$18.7B
AUM Growth
+$1.89B
(+11%)
Cap. Flow
+$1.31B
Cap. Flow
% of AUM
7.02%
Top 10 Holdings %
Top 10 Hldgs %
10.01%
Holding
3,237
New
779
Increased
845
Reduced
690
Closed
834
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$109M |
| 2 |
Norwegian Cruise Line
NCLH
|
+$105M |
| 3 |
Goldman Sachs
GS
|
+$104M |
| 4 |
Vertex Pharmaceuticals
VRTX
|
+$101M |
| 5 |
Steel Dynamics
STLD
|
+$99.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Chevron
CVX
|
+$176M |
| 2 |
Coca-Cola
KO
|
+$151M |
| 3 |
Broadcom
AVGO
|
+$146M |
| 4 |
Microsoft
MSFT
|
+$140M |
| 5 |
ExxonMobil
XOM
|
+$137M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 16.93% |
| 2 | Industrials | 11.65% |
| 3 | Consumer Discretionary | 11.56% |
| 4 | Healthcare | 11.56% |
| 5 | Financials | 11.45% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
AGS
1876
DELISTED
PlayAGS
AGS
| $163K | ﹤0.01% |
31,916
+7,437
| +30% | +$41.9K |
|
1877
First Trust Materials AlphaDEX Fund
FXZ
$366M
| $162K | ﹤0.01% |
2,677
-8,557
| -76% | -$512K |
|
1878
Invesco Senior Income Trust
VVR
$456M
| $162K | ﹤0.01% |
42,285
| – | – |
|
1879
Pacer Global Cash Cows Dividend ETF
GCOW
$3.43B
| $162K | ﹤0.01% |
5,100
+3,004
| +143% | +$91.1K |
|
1880
Lineage Cell Therapeutics
LCTX
$262M
| $161K | ﹤0.01% |
137,568
+34,246
| +33% | +$43.2K |
|
|
RPT
1881
Rithm Property Trust
RPT
$95.1M
| $160K | ﹤0.01% |
3,670
+1,269
| +53% | +$59.2K |
|
|
JMIA
1882
Jumia Technologies
JMIA
$716M
| $159K | ﹤0.01% |
+49,568
| New | +$224K |
|
1883
Diana Shipping
DSX
$266M
| $159K | ﹤0.01% |
51,141
-76,333
| -60% | -$244K |
|
|
RPTX
1884
DELISTED
Repare Therapeutics
RPTX
| $157K | ﹤0.01% |
10,664
-1,569
| -13% | -$23.5K |
|
1885
Fidelity MSCI Financials Index ETF
FNCL
$2.38B
| $155K | ﹤0.01% |
3,240
+2,742
| +551% | +$131K |
|
1886
Huadi International Group
HUDI
$10.7M
| $155K | ﹤0.01% |
+30,574
| New | +$597K |
|
1887
Matrix Service
MTRX
$313M
| $155K | ﹤0.01% |
24,879
+1,122
| +5% | +$5.8K |
|
|
KZR
1888
DELISTED
Kezar Life Sciences
KZR
| $155K | ﹤0.01% |
+2,195
| New | +$163K |
|
1889
Riverview Bancorp
RVSB
$109M
| $154K | ﹤0.01% |
20,040
+3,486
| +21% | +$24.7K |
|
1890
Beyond Air
XAIR
$3.78M
| $154K | ﹤0.01% |
59
-6
| -9% | -$15.3K |
|
1891
Invesco S&P 500 Equal Weight Consumer Discretionary ETF
RSPD
$322M
| $154K | ﹤0.01% |
+3,912
| New | +$152K |
|
1892
InfuSystem Holdings
INFU
$198M
| $153K | ﹤0.01% |
17,607
+3,649
| +26% | +$29.7K |
|
|
ASRT
1893
DELISTED
Assertio
ASRT
| $153K | ﹤0.01% |
+2,366
| New | +$104K |
|
1894
RPC Inc
RES
$1.14B
| $152K | ﹤0.01% |
17,043
-35,484
| -68% | -$320K |
|
1895
Caribou Biosciences
CRBU
$146M
| $151K | ﹤0.01% |
+24,025
| New | +$214K |
|
1896
CorMedix
CRMD
$570M
| $150K | ﹤0.01% |
35,645
+8,685
| +32% | +$30.7K |
|
1897
UroGen Pharma
URGN
$1.97B
| $150K | ﹤0.01% |
16,893
+3,604
| +27% | +$34.1K |
|
|
WMPN
1898
DELISTED
William Penn Bancorporation Common Stock
WMPN
| $150K | ﹤0.01% |
12,356
+1,074
| +10% | +$12.4K |
|
1899
First Trust Consumer Discretionary AlphaDEX Fund
FXD
$276M
| $150K | ﹤0.01% |
3,105
+488
| +19% | +$23.4K |
|
1900
iShares US Financial Services ETF
IYG
$2.15B
| $149K | ﹤0.01% |
2,841
+1,485
| +110% | +$77.8K |
|
Similar funds
Qube Research & Technologies (QRT)'s Q4 2022 Portfolio in Review
As of Q4 2022, Qube Research & Technologies (QRT) held 3,237 positions worth $18.7B, up 11% from $16.8B the previous quarter. Its ten largest holdings account for 10% of the portfolio.
Qube Research & Technologies (QRT) deployed $1.31B of net new capital in Q4 2022, opening 779 new positions and adding to 845 existing holdings. Its largest new stake was Bristol-Myers Squibb: 1,451,017 shares worth $104M.
By sector, the portfolio is most concentrated in Technology at 17% of assets, down from 21% a quarter earlier, followed by Industrials and Consumer Discretionary.
On the sell side, the largest reduction was Microsoft, an estimated $140M trimmed.
- Qube Research & Technologies (QRT)'s largest Q4 2022 buy was Bristol-Myers Squibb: 1,451,017 shares worth $104M.
- Qube Research & Technologies (QRT) added most to Goldman Sachs in Q4 2022, an estimated $104M increase.
- Qube Research & Technologies (QRT)'s biggest Q4 2022 reduction was Microsoft, cutting an estimated $140M.
- Qube Research & Technologies (QRT) fully exited Chevron in Q4 2022, selling an estimated $176M.
- Qube Research & Technologies (QRT)'s ten largest holdings make up 10% of its $18.7B portfolio in Q4 2022.
- Qube Research & Technologies (QRT) opened 779 new positions and closed 834 in Q4 2022.
- Qube Research & Technologies (QRT)'s portfolio value rose 11% quarter-over-quarter to $18.7B.
Based on Qube Research & Technologies (QRT)'s 13F filing for Q4 2022, filed 14 Feb 2023.